Michael J. Rosenberg

Michael’s experience includes advising:

Capital Markets

• MediWound Ltd, an Israeli based biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio therapeutic, non-surgical solutions for tissue repair and regeneration, in its US$30 million registered offering and concurrent private placement
• MediWound Ltd, an Israeli based biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio therapeutic, non-surgical solutions for tissue repair and regeneration, in its US$15 million registered offering
• The underwriters in connection with a convertible bond offering by Camtek
• SpringWorks Therapeutics in its US$186.3 million initial public offering and US$287.5 million follow-on offering*
• Scholar Rock Holding Corporation in its US$51 million and US$230 million public follow-on offerings*
• Research Alliance Corporation in its US$137 million initial public offering and concurrent private placement*
• Calliditas Therapeutics in its US$90 million initial public offering*
• Pliant Therapeutics in its US$165 million initial public offering*
• Kaleido Biosciences in its US$75 million initial public offering*
• Advaxis in its US$20 million shelf offering*
• Allena Pharmaceuticals in its US$20 million registered direct offerings*
• Vascular Biogenics in its US$18 million registered direct offerings*
• The underwriters in connection with Immunome’s US$35 million initial public offering*
• The underwriters in connection with a follow-on offering for IntriCon Corporation*
• Zealand Pharma in its US$89 million initial public offering*
• Edge Therapeutics in its US$115 million initial public offering*
• Iconix Brand Group in its offering of High Yield Convertible Notes*
• Griffon Corporation in its 144A offering of high yield debt securities*
• US Shale Solutions in its 144A offering in senior secured notes*
• The underwriters in connection with a follow-on offering for BioLineRx*
• Forward Pharma in its US$221 million initial public offering*

Venture Capital

• SpringWorks Therapeutics in its US$125 million Series B financing to advance two late-stage rare disease oncology programs toward potential regulatory approval*
• Navitor Pharmaceuticals in its Series D and Series C financings and issuance of convertible notes*
• Imara Pharma in its US$63 million Series B financing*

Mergers & Acquisitions

• ironSource, a software company that focuses on app monetization and distribution, on its US$4.4 billion all stock merger with Unity Software
• HUB Cyber Security on its US$1.28 billion business combination with Mount Rainier Acquisition Corp.
• Alpha Tau Medical, an Israel-based the developer of the alpha-radiation cancer therapy Alpha DaRT™, on its US$1 billion business combination with Healthcare Capital Corp., a special purpose acquisition company
• Itamar Medical, an Israeli based medical device and digital health company in its US$538 million sale to ZOLL Medical
• ironSource, a software company that focuses on app monetization and distribution, on its US$11 billion business combination with Thoma Bravo Advantage, a special purpose acquisition company
• Alpha Healthcare Acquisition Corp.’s business combination with Humacyte*
• Zealand Pharma’s US$205 million sale of certain royalty rights to Royalty Pharma*
• AM-Pharma’s sale of a minority interest in the company to Pfizer and related option payment*
• Dava Pharmaceuticals in its sale to Endo Pharmaceuticals*

*Matter handed prior to joining Latham